Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis.

by Nao Tokai, Shuzo Yoshida, Takuya Kotani, Ayaka Yoshikawa, Yuko Kimura, Youhei Fujiki, Yoko Matsumura, Tohru Takeuchi, Shigeki Makino, Shigeki Arawaka
Published 2018-01-01

Correction: Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis.

by Nao Tokai, Shuzo Yoshida, Takuya Kotani, Ayaka Yoshikawa, Yuko Kimura, Youhei Fujiki, Yoko Matsumura, Tohru Takeuchi, Shigeki Makino, Shigeki Arawaka
Published 2019-01-01